EUCTR2010-019079-32-GB进行中（未招募）1 期
A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 215
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason
- •2. Written informed consent has been obtained
- •3. Written Authorization for Use and Release of Health and Research Study
- •Information (US sites only) has been obtained
- •4. Written Data Protection Consent (European sites only) has been obtained
- •5. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
- •6. Willing to follow instructions and likely to complete all required visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemPatients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration).EUCTR2010-019079-32-PTAllergan Limited290
进行中（未招募）
不适用
A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemPatients who participated in a previous intravitreal Brimo PS DDS study, including 190342-036 (Subjects undergoing pars plana vitrectomy for posterior segment diseases)EUCTR2010-019079-32-CZAllergan Limited300
进行中（未招募）
不适用
A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemEUCTR2010-019079-32-DEAllergan Limited290
未知
不适用
TRAVOPROST 0.004% IN PEDIATRIC GLAUCOMA PATIENTS-H40H40PER-014-13ALCON RESEARCH LTD.,
招募中
2 期
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND)Parkinson's disease2024-513548-27-00Neuroderm Ltd.42